Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

A single round of prostate cancer screening that included a prostate-specific antigen (PSA) test, a kallikrein panel, and an MRI detected one additional high-grade cancer per 196 men and one low-grade ...

There is both good news and bad news about prostate cancer screening. First, the bad news: the blood test involved, which measures a compound called prostate-specific antigen (PSA), is too inaccurate.

While many people are familiar with mammograms and smear tests, prostate screening is talked about far less.To shed light on this important subject ahead of Prostate Cancer Awareness Month in March, ...

A deep learning model was as effective as radiologists in detecting clinically significant prostate cancer on multiparametric MRI, a retrospective study suggested. In an internal test set of 400 ...

An artificial intelligence system slightly outperformed radiologists using PI-RADS at detecting clinically significant prostate cancer. A trained artificial intelligence (AI) system discriminated ...